NCT06826898

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness of the use of a novel crosslinking hyaluronan hydrogel on the prevention of the adhesion occurrence after anterior talofibular ligament repair surgery. With applying crosslinking hyaluronan hydrogel, the range of motion (ROM) of the ankle is expected to be better than sham group.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 10, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 14, 2025

Completed
15 days until next milestone

Study Start

First participant enrolled

March 1, 2025

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Completed
Last Updated

February 14, 2025

Status Verified

February 1, 2025

Enrollment Period

1.2 years

First QC Date

February 10, 2025

Last Update Submit

February 10, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Range of Motion (ROM)

    Measure the range of plantar flexion, dorsiflexion, inversion, and eversion of the ankle.

    day 14

Secondary Outcomes (7)

  • Range of Motion (ROM)

    baseline, day 28, 49, 70

  • Anterior Talar Translation (ATT)

    baseline, day 14, 28, 49, 70

  • Visual Analogue Scale (VAS) for pain

    baseline, day 14, 28, 49, 70

  • Cumberland Ankle Instability Tool (CAIT) questionnaire

    baseline, day 14, 28, 49, 70

  • American Orthopedic Foot and Ankle Society (AOFAS) questionnaire

    baseline, day 14, 28, 49, 70

  • +2 more secondary outcomes

Study Arms (2)

Absorbable Adhesion Barrier

EXPERIMENTAL

DEFEHERE Absorbable Adhesion Barrier, 1.0 mL/syringe

Device: DEFEHERE Absorbable Adhesion Barrier

Sham

SHAM COMPARATOR

conventional therapy without using any antiadhesion product

Device: Sham (No Treatment)

Interventions

DEFEHERE Absorbable Adhesion Barrier, 1.0 mL/syringe

Absorbable Adhesion Barrier

conventional therapy without using any antiadhesion product

Sham

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Voluntarily participate and sign an informed consent form; 1.2 Age 18 to 60 years of male or female; 1.3 Patients experiencing lateral ankle pain discomfort, confirmed by MRI to have anterior talofibular ligament (ATFL) injury; 1.4 History of recurrent ankle inversion sprains three times or more, with no improvement after six months of conservative treatment, and scheduled for ATFL repair surgery; 1.5 Willing to comply with all follow-up requirements of the trial protocol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Show Chwan Memorial Hospital

Changhua, Taiwan

RECRUITING

Central Study Contacts

Yan-Yu Chen Doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 10, 2025

First Posted

February 14, 2025

Study Start

March 1, 2025

Primary Completion

April 30, 2026

Study Completion

June 30, 2026

Last Updated

February 14, 2025

Record last verified: 2025-02

Locations